The firm, whose products include a treatment for varicose veins and anti-venom drugs, said it expected 2014/15 revenues to be slightly above an upgraded forecast range of 345 million pounds to 360 million pounds given in February.

It said the higher forecast reflects the acquisition of lung device company PneumRx, which completed in January.

The company is also forecasting strong revenue growth in its current 2015/16 fiscal year, giving a range of 410 million pounds to 440 million pounds, based on constant currency.

(Reporting by Neil Maidment; editing by David Clarke)